Cost-effectiveness of selective therapy for clinical mastitis based on on-farm pathogen identification

Abstract

ABSTRACT This research aims to describe the cost-benefit analysis of selective therapy adoption for clinical mastitis based on the identification of pathogens using on-farm culture system. A survey of clinical mastitis cases was carried out in the database of a dairy herd with 500 lactating Holstein cows, during the period of September 2017 to October 2019. Variables such as frequency of cases, main pathogens identified, costs with antibiotic therapies and milk disposal were evaluated and compared between one year before (P1) and after (P2), the farm's selective therapy adoption. During the study period, 599 cases of clinical mastitis were identified, 361 in P1 and 238 in P2. The average cost of therapies was US74.33 and US91.82 for P1 and P2. Considering the two years of the study, the estimated cost of treating clinical mastitis was US45,444.31, of which US$27,559.97 were spent in P1 and US17,884.34 in P2. Based on the result of the identification of the pathogen types associated with clinical mastitis, selective therapy demonstrated cost reduction already in the first year of implementation.